51S Stock Overview
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.12 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.05 |
| Beta | 0.91 |
| 11 Month Change | -5.56% |
| 3 Month Change | 16.67% |
| 1 Year Change | 100.00% |
| 33 Year Change | -54.58% |
| 5 Year Change | -82.24% |
| Change since IPO | -60.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.0% | -0.7% | 0.2% |
| 1Y | 100.0% | -17.2% | 8.5% |
Return vs Industry: 51S exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 51S exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 51S volatility | |
|---|---|
| 51S Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 51S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 51S's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| 51S fundamental statistics | |
|---|---|
| Market cap | €24.24m |
| Earnings (TTM) | -€6.08m |
| Revenue (TTM) | €1.45m |
16.8x
P/S Ratio-4.0x
P/E RatioIs 51S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51S income statement (TTM) | |
|---|---|
| Revenue | AU$2.32m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.32m |
| Other Expenses | AU$12.06m |
| Earnings | -AU$9.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 100.00% |
| Net Profit Margin | -420.82% |
| Debt/Equity Ratio | 0% |
How did 51S perform over the long term?
See historical performance and comparison